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Abstract 
We identified de novo nonsense variants in KIDINS220/ARMS in three unrelated patients with spastic 
paraplegia, intellectual deficit, nystagmus, and obesity. KIDINS220 is an essential scaffold protein 
coordinating neurotrophin signal pathways in neurites and is spatially and temporally regulated in the 
brain. Molecular analysis of patients’ variants confirmed expression and translation of truncated 
transcripts similar to recently characterized alternative terminal exon splice isoforms of KIDINS220.  
KIDINS220 undergoes extensive alternative splicing in specific neuronal populations and 
developmental time points, reflecting its complex role in neuronal maturation. In mice and humans, 
KIDINS220 is alternative spliced in the middle region as well as in the last exon. These full-length and 
KIDINS220 splice variants occur at precise moments in cortical, hippocampal, and motor neuron 
development, with splice variants similar to the variants seen in our patients and lacking the last exon 
of KIDINS220 occurring in adult rather than in embryonic brain. We conducted tissue-specific 
expression studies in zebrafish that resulted in spasms, confirming a functional link with disruption of 
the KIDINS220 levels in developing neurites. This work reveals a crucial physiological role of 
KIDINS220 in development and provides insight into how perturbation of the complex interplay of 
KIDINS220 isoforms and their relative expression can affect neuron control and human metabolism. 
Altogether, we here show that de novo protein-truncating KIDINS220 variants cause a new syndrome, 
SINO, characterized by spastic paraplegia, intellectual deficit, nystagmus, and obesity. This is the first 
report of KIDINS220 variants causing a human disease.  
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Introduction 
Next Generation Sequencing (NGS) techniques provide a time and cost-efficient method to identify 
novel genes. We used this approach to investigate two patients presenting with an apparently unique 
combination of features, including obesity, spastic paraplegia, intellectual deficit, nystagmus, and 
macrocephaly and identified different, de novo, heterozygous, nonsense variants in KIDINS220 in each 
patient. A third patient with similar features was ascertained through DECIPHER 
(decipher.sanger.ac.uk) after the DDD study shared a de novo candidate variant identified by trio 
exome analysis (1, 2).  
KIDINS220 (Kinase D interacting substrate of 220 kDa), also known as ARMS (Ankyrin Repeat-rich 
Membrane Spanning), is a conserved scaffold protein that controls axonal and dendritic maturation (3, 
4). The spatiotemporal expression of different KIDINS220 isoforms is finely tuned in the mammalian 
brain, and knock-out Kidins220 animals show developmental central nervous system anomalies (5-7). 
Recently it was shown that distinctive neuronal populations express different KIDINS220 splice 
isoforms at specific times during development, including newly characterized alternative terminal 
exon splice isoforms (8). The expression of the complete range of these isoforms, with the 
corresponding domains for thus far poorly characterized interaction partners, may be crucial for proper 
neuronal development. We show here that our patients’ variants result in truncated isoforms of 
KIDINS220 similar to an alternative terminal exon splice isoform expressed mainly during adulthood. 
Our patients’ neurological phenotype may be caused by disruption of full-length KIDINS220 splice 
isoform repertoire expression and lack of essential interaction domains that are necessary during 
embryonic development of the neural network. We further show that perturbation of KIDINS220 levels 
causes a spasticity phenotype in zebrafish. We therefore suggest that KIDINS220 variants cause a new 
syndrome characterized by spastic paraplegia, intellectual deficit, nystagmus, and obesity (SINO 
syndrome).  
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Results  
De novo KIDINS220 variants are implicated in patients with a unique phenotype of spastic 
paraplegia, intellectual deficit, nystagmus and obesity  
We performed NGS analysis in three unrelated patients with spastic paraplegia, intellectual deficit, 
nystagmus, and obesity (Figure 1 and Table 1, Supplement I).  
Two patients were sequenced for a targeted gene panel of 582 genes to investigate the suspected 
genetic cause of syndromic and non-syndromic obesity (OBESITOME, UMC Utrecht, 
Netherlands)(Supplemental Table 1). We identified heterozygous KIDINS220 variants, 
NM_020738.2:c.4050G>A, p.(Trp1350*), and NM_020738.2:c.4096C>T, p.(Gln1366*), in patient 1 
and 2, respectively. Both variants result in a premature stop codon.  Their de novo occurrence was 
confirmed by Sanger sequencing of both patients and their parents. There were no further de novo 
variants in other shared genes on the OBESITOME panel. Independently, whole exome sequencing on 
patient 3 revealed a heterozygous de novo insertion of an A nucleotide, NM_020738.2:c.4520dup, 
resulting in a frameshift and predicted premature truncation of the protein p.(Leu1507Phefs*4) (1, 
2)(Figures 2A and 2B).  
 
Variant KIDINS220 RNA expression results in truncated KIDINS220 in patient fibroblasts and 
HEK293T cells  
All variants identified here fall within the last two exons of the gene (Figure 2A and 2B). Sanger 
sequencing on fibroblast cDNA from patient 1 showed that variant c.4050G>A resulted in proper 
mRNA expression (Figure 2C). This result was confirmed by Quantitative PCR, with the relative 
expression of KIDINS220 before and after the variant c.4050G>A equal in patient fibroblast cDNA 
compared to control fibroblast cDNA, indicating that the shortened transcript escaped nonsense-
mediated decay (NMD) (data not shown). The mammalian NMD pathway is unable to recognize 
premature termination codons in the last exon and the last ~55 bp of the penultimate exon (9). 
Shortened mRNA transcripts that escape NMD are translated into truncated protein products possibly 
lacking important C-terminal domains.  Variants in the penultimate exon resulting in premature stop 
codons that escape NMD are reported in other syndromes, for example, autosomal dominant Robinow 
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syndrome (10).  Furthermore, we used cDNA sequencing to assess known alternative splicing of exon 
25 and exon 26 in the middle region of KIDINS220, which has not yet been determined in fibroblast 
cells. Patient and control cDNA sequencing of the region flanking and containing exons 25 and 26 
revealed that fibroblasts from both our patient 1 and control express KIDINS220 with exon 26 
removed by alternative splicing (Genbank Accession Number KJ812120), indicating that exon 26 is 
removed in all fibroblast cells (data not shown).  
We analyzed total protein extract of fibroblasts of patient 1 by Western blot analysis and detected a 
150 kDa band in addition to the 220 kDa wild-type KIDINS220 band, confirming expression of the 
truncated, Trp1350* protein (Figure 2D). The variants of patient 1 and 2 were also overexpressed 
separately in HEK293T cells to visualize the size of the truncated protein products, using human 
isoform containing both exon 25 and exon 26 (Genbank Accession Number KJ812119)(8). The 
presence of a 150 kDa protein coinciding with the p.(Trp1350*) variant of patient 1 and a 167 kDa 
protein coinciding with the p.(Gln1366*) variant of patient 2 were detected by Western blot. Only 
wild-type 220 kDa protein was identified in HEK293T extracts overexpressing the wild-type 
KIDINS220 (Figure 2E). The KIDINS220 protein product of these variants is strikingly similar to that 
produced by alternative terminal exon (ATE) splicing in mouse and humans (ATE C2) (Figure 2B) 
(8).  
 
Motor neuron specific expression of KIDINS220 variants induces spasms in zebrafish 
Zebrafish is a powerful, versatile vertebrate model to study human motor neuron diseases (11, 12). By 
using the Gal4/UAS approach (13, 14) we achieved motor neuron-specific expression of human 
KIDINS220 variants in zebrafish embryos and analyzed their effect in vivo. Transgenic 
tg(Isl1BAC:GalFF) fish used here constitutively express Gal4 in motor neurons; when DNA constructs 
containing an upstream activation sequence (UAS) driving transcription are supplemented by 
microinjection, mosaic larvae are obtained in which Gal4 binds to the UAS sequence to express 
KIDINS220 solely in motor neurons. Embryos tg(Isl1BAC:GalFF) microinjected with 
UAS:KIDINS220 wild-type or variant p.(Trp1350*) displayed spasms in the trunk at 5 days post 
fertilization (dpf), confirming a functional link between spasticity and disruption of KIDINS220 levels 
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and/or function (Figure 3). This was slightly more evident in embryos expressing the mutant 
KIDINS220. Representative recordings of the spasm phenotypes can be found in the Supplemental 
material online.  
 
Kidins220 variants do not result in different cellular localizations in Neuro-2A cells 
During differentiation, KIDINS220 is transported to the neurite tips of PC12 neuronal cells, a process 
that is altered in KIDINS220 isoforms with an alternative terminal exon (4, 8). We examined the 
cellular location of wild-type and truncated KIDINS220 in Neuro-2A cells, a cell line where 
KIDINS220 is endogenously expressed, albeit at lower levels than in PC12 cells (4). Following 
cotransfection of HA-tagged wild-type or p.(Gln1366*) KIDINS220 as well as a mCherry reporter, 
Neuro-2A cells were differentiated with retinoic acid for a total of 5 days. Fixation was performed at 
day 5 and immunofluorescence performed with an anti-HA antibody. Differentiated cells expressing 
wild-type or p.(Gln1366*) exhibited localization of KIDINS220 throughout the entire cell body, as 
well as in the neurite tips. There was no difference in the cellular localization of the wild-type or 
variants (Figure 4).  
 
Discussion 
KIDINS220 controls axonal and dendritic maturation in the developing mammalian brain, and is 
integral to the branching, stabilization, and complexity of cortical and hippocampal dendrites (3, 4, 7). 
The cytoplasmic N-terminus contains 11 ankyrin repeats. There are four transmembrane segments in 
the central part of the molecule (15). The C-terminal tail, also exposed to the cytoplasm, contains 
several protein-protein interacting domains: a proline-rich domain, Sterile Alpha Motif (SAM), 
Kinesin Light Chain (KLC) - Interactive Motif (KIM) and PDZ binding motif (3, 16). These domains 
enable the recruitment of cell-specific adaptors and effectors to activated Tropomyosin receptor 
Kinases (TrK) and are involved in functional interactions with other receptors such as the Glutamate, 
Ephrin and Vascular Endothelial Growth Factor receptors (6, 17). The KIM domain mediates 
intracellular trafficking of KIDINS220 through direct binding to KCL-1 and -2 and is important for a 
correct response to neurotrophic stimuli (16, 18). Expression of KIDINS220 is developmentally 
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regulated and differential splicing occurs in specific tissues such as the brain, heart, and skeletal 
muscle. The alternative splicing is complex and developmental occurrence of KIDINS220 splice 
isoforms with the middle region and/or last exon removed varies in cortical, hippocampal and motor 
neurons(8). Schmieg et al. demonstrated in mice that KIDINS220 with exon 30 included is expressed 
in embryonic tissue; in contrast, a similar KIDINS220 splice variant lacking exon 30 is present solely 
in adult tissue. Motor neurons exhibited the highest variety of alternative splicing in the middle region, 
but did not exhibit any alternative terminal exon splicing at any time during development (8). Our 
patients’ variants result in isoforms similar to KIDINS220 splice variants with alternative terminal 
exon splicing. The constitutive expression of truncated isoforms similar to alternative terminal exon 
splice isoforms that are not usually expressed in the developing embryo or present in motor neurons, 
may perturb the complex splice regulation necessary for proper neurite development and result in the 
phenotype seen in our patients.  
In this manuscript we show that KIDINS220 nonsense variants are causal for a characteristic 
phenotype most likely due to disruption of the repertoire of splice isoforms available for developing 
neuronal populations. Interference in the delicate balance of KIDINS220 isoform expression in the 
neurite tips will impede the various Neurotrophin, Glutamate, Ephrin and Vascular Endothelial 
Growth Factor receptor associations required for correct neuronal network development. The C-
terminal region of KIDINS220 contains the KIM and PDZ domains that are required for protein 
interactions and transport. Lack of the KIM domain and its interaction with KCL-1 subunit KIF5A 
(Kinesin Family Member 5A) impairs protein transport to newly formed neurite tips (16). Similarly, 
absence of a PDZ domain will interfere with the interaction of KIDINS220 with SNX27 (Sorting 
Nexin Family Member 27), an important protein for transport to the plasma membrane (19). We here 
show in KIDINS220 transfected Neuro-2a cells, both wild-type and KIDINS220 variant p.(Gln1366*) 
successfully localized to the differentiating neurite tips, indicating an alternate as-of-yet undetermined 
molecular pathology due to the variants seen in our patients.  
Studies of Kidins220 during zebrafish and Xenopus Laevis embryogenesis showed dynamic 
expression in the nervous system including the hypothalamus, eye, branchial arches, heart and somites, 
partly correlating with the anomalies observed in our patients (20, 21). Mice completely lacking 
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Kidins220 are not viable (5-7). The extensive neuronal cell death in the brain of mutant embryos 
results in abnormal ventricle enlargement. This observation appears concordant with the pre- and post-
natal ventriculomegaly observed in our patients. Heterozygous mice display defects in dendritic 
growth and branching, indicating the role of Kidins220 in Brain-Derived Neurotrophic Factor 
(BDNF)-induced dendritic development (6, 7, 22). Although the heterozygous and wild-type mice 
have, at several age time points, comparable total Kidins220 protein levels in the brain, it seems likely 
that the temporal balance between Kidins220 isoforms in the brain is crucial for correct neural 
development (5). Structural cardiac anomalies and defects of the vascular and immune system were 
also observed in Kidins220 -/- embryos(5, 6), but are not seen in any of our patients, possibly due to 
different isoforms being required for normal heart and brain development (8).  
Zebrafish is an excellent model for human motor neuron disorders (11). Motor neuron-specific 
expression in zebrafish using the wild-type or variant p.(Trp1350*) KIDINS220 resulted in spasms. 
The observed difference in the induction of spasms in zebrafish embryos expressing the wild-type or 
p.(Trp1350*) truncated KIDINS220 may reflect the complex regulation of KIDINS220 tissue-specific 
splicing and expression. More conclusively, disruption of KIDINS220 expression levels in motor 
neurons functionally links KIDINS220 deregulation to nervous system impairment. The specific 
features in our zebrafish model, in particular the presence of spasms that are not observed in affected 
humans, confirm the effects of KIDINS220 perturbation on neuronal function but are also likely to 
reflect anatomical differences in the central nervous system between zebrafish and humans. 
Specifically, the absence of corticospinal and rubrospinal tracts in zebrafish results in the replication of 
human lower motor neuron disorders more faithfully than human upper motor neuron disorders on the 
phenotypical level. KIDINS220 is expressed in cortical and hippocampal neurons, encompassing the 
upper motor neuron system, and as such this dysfunction can be classified as an upper motor neuron 
disorder. Nonetheless, zebrafish have provided a suitable partial model for insights into the molecular 
and genetic mechanisms of other upper motor neuron disorders, such as hereditary spastic paraplegias 
(24-26).  
The pathophysiology of obesity is difficult to explain. KIDINS220 is known to act as a downstream 
substrate for protein kinase D and mediates multiple receptor signaling including BDNF and other 
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neurotrophins. Since neurotrophins have been implicated in the molecular and cellular processes 
underlying body weight regulation, disruption of this finely tuned TrK pathway could possibly explain 
the obesity phenotype in these patients (27, 28). Increased expression of KIDINS220 has been linked 
with perturbation of TrkA/p75 neurotrophin receptor complex association and overexpression of the 
differently spliced KIDINS220 ATE C2 leads to a substantial increase in TrkA expression (8, 23). 
Further research is needed to provide insight into this interaction.  
Not every loss-of-function variant in the last exon of KIDINS220 causes the phenotype observed in our 
patients as illustrated by the presence of three KIDINS220 variants that are present heterozygously in 
five healthy individuals in the Exome Aggregation Consortium database (Exome Aggregation 
Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) accessed September 
2015). These variants, resulting in p.Glu1530Ter, p.Arg1736Ter and p.Ser1740Ter, are shortly after 
the variant in our patient 3, pointing to a specific effect of the variants presented in this study. 
Our patients manifest similarities with MOMO Syndrome (Macrosomia, Obesity, Macrocephaly and 
Ocular abnormalities; OMIM 157980), however prenatal ventricular dilatation and spastic paraplegia 
are not features of this condition. KIDINS220 Sanger sequencing of ten MOMO patients did not yield 
any variants. We therefore suggest that our patients have a distinct syndrome characterized by Spastic 
paraplegia, Intellectual disability, Nystagmus and Obesity (SINO). 
In conclusion, we show here that de novo heterozygous nonsense KIDINS220 variants cause SINO 
syndrome. This is the first report of KIDINS220 variants causing a human disease. Future research 
might provide more insights in the role of KIDINS220 in the pathogenesis of spastic paraplegia and 
obesity.  
 
Materials and Methods 
Clinical Features 
The clinical features of the three patients are summarized in Figure 1 and Table 1 and case reports can 
be found in Supplement I.  
Next generation sequencing and analytical pipeline 
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NGS on patients 1 and 2 was performed with fragment libraries prepared and enriched for the genomic 
regions of interest using a 1M custom OBESITOME microarray (Agilent Technologies, Santa Clara, 
CA, USA) as previously described (29, 30). The OBESITOME contained 582 obesity-related genes, 
with the genes selected on presumed obesity relevance from several databases, pathway sources, and 
research articles (Supplemental Table I). The OBESITOME consisted of 55 samples that were pooled 
and run as a full slide on the SOLiD 5500XL (Life Technologies, Carlsbad, CA). Color space reads 
were mapped and aligned against GRCh37/hg19 reference genome using a custom pipeline based on 
the BWA software and annotated as described previously (31, 32). Mean sample coverage for the 
entire run of 55 samples on the OBESITOME was 100X, median coverage was 87X and 85% of 
genomic positions were covered by more than 20 reads. The mean coverage for patient 1 and 2 was 
161X and 170X, respectively. The criteria for variant detection coverage were set at 10 unique reads, 
and a non-stringent cut-off for heterozygote allele calls was set at 25-75%. Variants were filtered 
against the reference frequencies from the datasets of NCBI dbSNP Build 137 for Human 
(https://www.ncbi.nlm.nih.gov/SNP), Exome Variant Server (EVS) 
(http://evs.gs.washington.edu/EVS), 1000Genomes (http://www.1000genomes.org), Genome of the 
Netherlands (http://www.nlgenome.nl) or our in-house dataset, with novel variants and rare variants 
less than a 0.5% minor allele frequency threshold retained for further analysis.  For each patient, a 
final variant list was compiled including the location in the genomic sequence of the variant, the amino 
acid change and prioritized on the conservation score and predicted effect on protein function using 
prediction programs (GERP, Polyphen2, SIFT). Confirmation and segregation analysis in the family of 
the selected single nucleotide variants or small insertions and deletions was performed by Sanger 
sequencing.  
Whole exome sequencing and analysis for patient 3 was performed as described by the Deciphering 
Developmental Disorders (DDD) study (1, 2). DNA of patient 3 was extracted from saliva samples 
and exome capture performed using Agilent Sureselect 55 MB Exome Plus (Agilent Technologies, 
Santa Clara, CA, USA). Exomes were sequenced on the Illumina HiSeq (Illumina, San Diego, CA, 
USA) and de novo analysis performed using DeNovoGear (33). De novo variants were validated using 
Sanger sequencing. 
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All variants have been submitted to the Leiden Open Variation Database (LOVD) located at 
http://databases.lovd.nl/shared/genes/KIDINS220.  
 
KIDINS220 Sanger sequencing in a MOMO cohort and patient cDNA 
To determine if variants within KIDINS220 were causal for MOMO syndrome, the full coding regions 
and exon-intron boundaries of KIDINS220 were analyzed in a cohort of 10 MOMO patients by Sanger 
sequencing.  
To evaluate the impact of KIDINS220 variants on RNA expression on our patients, total RNA was 
isolated from fibroblasts of patient 1 using TRizol Reagent (ThermofFisher Scientific, Waltham, MA, 
USA) and converted to cDNA with the High-Capacity cDNA Archive Kit (Life Technologies, 
Carlsbad, CA, USA). Material from patients 2 and 3 was not available. Sanger sequencing on the full 
cDNA of patient 1 was performed. Furthermore, Quantitative PCR was performed on cDNA of both 
patient and control fibroblasts using primers before and after the variant c.4050G>A to evaluate if 
expression of the mRNA was reduced compared to the control. Primer sequences: 5’- 
CCTGAAGACCCACGTTTCC-3’ / 5’- AAGCTGAAGTTGAGTGTGTAGG-3’ and 5’- 
GCTCAGATGTCCCAGTTAGAAG-3’ / 5’- CTGATGAACTCTGACCCATGTAATA-3’.  
 
Fibroblast and HEK293 protein preparation and immunoblotting 
Fibroblasts of patient 1 and control samples were cultured, lysed, and Western blot analysis performed 
on the total protein using an antibody recognizing the N-terminus of KIDINS220 (34). Fibroblasts of 
patient 1 and control samples were cultured according to standard conditions. Frozen cell pellets were 
lysed at 4°C in 50mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton, 1% Na-deoxycholate, 0.1% SDS 
and 2mM EDTA pH8.0 in the presence of protease inhibitors (cOmplete, Roche, Basel, Switzerland) 
and phosphatase inhibitors (PhosSTOP, Roche, Basel, Switzerland) for 30 min, and sonicated for 10 
seconds. Samples were spun for 5 minutes at 13.000rpm at 4°C.  
Western blot analysis was then performed on the total protein extract of the patient fibroblasts using an 
antibody recognizing the N-terminus of KIDINS220 (34). The supernatant was diluted in 2x Sample 
buffer (8% SDS/25% Glycerol/0.05M Tris pH 6.8/200mM DTT/ Bromophenol Blue/H2O) and 
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separated on 6% or 8% SDS-PAGE gels, followed by blotting onto PVDF membranes (Biorad, 
Veenendaal, Netherlands). Blots were blocked with either 2% BSA/0.05% Tween/PBS and incubated 
overnight with the KIDINS220 antibody. Blots were washed with 0.05%Tween/PBS for 3 times 10 
minutes each at room temperature and incubated with the appropriate secondary antibody. After 
washing 3 times in 0.05% Tween/ PBS and once in PBS, blots were developed with Pierce Enhanced 
Chemiluminescent Western Blotting Substrate (Life Technologies, Carlsbad, CA, USA). 
To visualize the molecular weight of the truncated proteins of patients 1 and 2, we introduced the 
identified point variants in HEK293T cells and performed Western blot analysis on the total protein as 
described above. HEK293T cells were grown at 37°C and 5% CO2 in DMEM: HAMF10 (1:1) 
medium containing 10% FBS and 1% penicillin/streptomycin. The wild-type KIDINS220 sequence 
corresponding to the long isoform of human KIDINS220 (Genbank Accession Number KJ812119) was 
obtained from an expression construct by using full-length KIDINS220 primers (primers available 
upon request) (16).  Wild-type KIDINS220 was ligated into the TOPO entry plasmid pCR8/GW/TOP 
(Life Technologies BV, Bleiswijk, the Netherlands) and the mutations encoding for Trp1350* and 
Gln1366* were engineered into the KIDINS220 expression construct using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and custom designed primers. The 
presence of the introduced mutations was confirmed by Sanger sequencing. HEK293T cells were 
transiently transfected with wild-type and variant DNA constructs using Polyethylenimin 
(Polyscience, Eppelheim, Germany), grown for 24 hours after transfection and prepared and analyzed 
as described above. 
 
Zebrafish expression construct and microinjections in zebrafish embryos 
The wild-type KIDINS220 cDNA sequence or the patient variant Trp1350* were introduced into 
pCR8/GW/TOPO. The KIDINS220 middle entry vectors were then used in a multi-site Gateway 
reaction (ThermoFisher Scientific, Waltham, MA, USA) together with p5E-UAS, p3E-IRES-EGFPpA 
and as destination vector pDestTol2pA3 (35) to obtain UAS:KIDINS220 expression vectors. Circular 
plasmid DNA of UAS:KIDINS220 constructs was injected at 30 ng/µl in the presence of 25 ng/µl Tol2 
mRNA into tg(Isl1BAC:GalFF; UAS:GFP) (14) embryos at the 1-cell stage together with 10 ng/µl 
 at K
ing's College London on M
arch 31, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
13 
 
pT2ZUASRFP as a fluorescent reporter (36). Healthy embryos displaying robust Isl1-specific RFP 
fluorescence at 5dpf were used for spastic activity recordings.  
 
Zebrafish High Speed Imaging 
Embryos at 5 dpf were mounted in 3% methylcellulose (Sigma-Aldrich, Zwijndrecht, the Netherlands) 
prepared in E3 embryonic medium prior to imaging for 20-60 seconds with a Hamamatsu C9300-221 
high speed CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) at 82-165 fps mounted on a 
Leica DM IRBE inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany) at room 
temperature using Hokawo 2.1 imaging software (Hamamatsu Photonics GmbH, Herrsching am 
Ammersee, Germany). Image analysis was subsequently carried out with ImageJ 
(http://rsbweb.nih.gov/ij/). Fischer’s exact test was employed to determine significance between 
Zebrafish groups with different construct injections.  
 
Transfection and immunofluorescence of transfected Neuro2A cells 
GW1-MCS expression constructs with a N-terminal HA tag were created with wild-type or 
p.(Gln1366*) KIDINS220 inserts. Neuro-2A cells were seeded at 10,000 cells/cm2 on poly-L-lysine 
coated 10 mm coverslips and grown for 24 hours in DMEM supplemented in 10% FCS and 
penicillin/streptomycin. The following day, cells were transfected in DMEM only using 
Lipofectamine2000 (Thermo Fischer Scientific, Waltham, MA, USA) with N-terminal HA-tagged 
wild-type or p.(Gln1366*) KIDINS220 in the GW1-MCS expression vector and cotransfected with a 
pcDNA/FRT/TO/mCherry expression construct. Cells were incubated for 4 hours at 37°C and 5% 
CO2 and medium removed, washed with PBS and replaced with differential medium (DMEM, 1% 
FCS, 5 uM retinoic acid). Cells were differentiated for 5 days, and differential medium was replaced 
after 2 and 4 days. 
For fixation, medium was removed, the cells were washed once with PBS, and the coverslip treated 
with 4% PFA (paraformaldehyde) for 15 minutes at room temperature before being washed again with 
PBS. Cells were then permeabalized with 0.1% TritonX100 in PBS for 20 minutes, washed with PBS, 
blocked in 3% BSA/PBS (bovine serum albumin) for 20 minutes, and washed again. The coverslip 
 at K
ing's College London on M
arch 31, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
14 
 
was then incubated with 2 ug/ml rabbit Anti-HA-tag antibody Chip Grade in 3% BSA/PBS (ab9110; 
Abcam, Cambridge, UK) overnight at 4°C. Coverslips were washed three times in PBS and probed 
with 1:1000 polyclonal goat anti-rabbit CY5 (Jackson ImmunoResearch, West Grove, PA, USA) in 
3% BSA/PBS for one hour at room temperature. Cells were washed 3 times in PBS and then stained in 
1:5000 DAPI (Thermo Fisher Scientific, Waltham, MA, USA), in 3% BSA/PBS for 15 minutes, 
washed 3 times in PBS, and mounted using Vectashield Antifade Mounting Medium (Vector 
Laboratories, Burlingame, CA, USA). Coverslips were visualized using a TCS SP8 Confocal Laser 
Scanning Platform (Leica, Wetzlar, Germany).  
  
Study Approval 
Written informed consent from the parents of the all three patients was received prior to inclusion in 
this study.   
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Legends to Figures:  
Figure 1: Clinical features of patients.  Note obesity, macrocephaly, brachycephaly and eye 
abnormalities. 
Figure 2: De novo dominant nonsense variants in KIDINS220 A) Variants p.(Trp1350*) and 
p.(Gln1366*) result in truncated protein without the full KIM domain, and p.(Leu1507Phefs*4) results 
in a slightly longer protein containing the full KIM domain.   B) Comparison of the wild-type 
KIDINS220 exonic structure versus an alternate terminal ending splice variant described by Schmieg 
et al.(8) and the three patients described in this study C) KIDINS220 cDNA sequencing verifies that 
there is no mRNA nonsense mediated decay in patient 1. Western blot analysis of (D) total extracts 
from patient 1 versus a control fibroblast and (E) total HEK293T extracts expressing wild-type and 
variant (Trp1350* and Gln1366*) forms of KIDINS220. Expression of KIDINS220 was tested with 
antibodies against the N-terminal part of KIDINS220 (Nterm Ab). The truncated protein products 
caused by KIDINS220 variants are indicated with a black arrow and the expected full-length wild-type 
protein product by a grey arrow. Anti-actin was used as a loading control for the fibroblasts and anti-
tubulin for the HEK293T cells. 
Figure 3. Effect of KIDINS220 and Trp1350* expression in zebrafish embryo motor neurons. 
A) Tissue-specific expression of KIDINS220 variants in 5 dpf zebrafish embryos was achieved by 
microinjection of UAS:KIDINS220 and UAS:Trp1350* DNA in  tg(Isl1BAC:GalFF; UAS:GFP) 
embryos (upper panel). A DNA UAS:RFP construct was co-injected (lower panel) to evaluate the 
efficiency of the microinjections. White arrowheads: axonic extensions of the motor neurons. B) 5 dpf 
zebrafish embryo (ventral view; anterior is left). White dotted line: position of kymographs presented 
in C. C) Visualization of spastic activity on thoracic kymographs. Representative kymographs of 
embryos showing no spastic activity (upper panel, no act.) and spastic activity (lower panel, spasm). 
Black arrowheads point at spastic events as visualized on the kymograph. Representative recordings 
are available as supplementary files. D) Quantification of spastic events in the different conditions of 
the study. Expression of KIDINS220 wt and Trp1350* in motor neurons results in increased spastic 
activity. No act.: No spastic activity. *:p<0.05; **:p<0.01; Fisher’s exact test. Scale bars: 1mm in A 
(left panels),B; 50 microns in A (right panels) 
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Figure 4: Kidins220 truncated variant is able to localize to neurite tips in Neuro-2A cells 
Representative image of transfected KIDINS220 wild-type and variant p.(Gln1366*) in differentiated 
Neuro-2A cells. Immunofluorescence of cotransfected mCherry (red), anti-HA-tagged wild-type or 
p.(Gln1366*) KIDINS220 (green) show that the truncated KIDINS220 variant is transported to 
developing neurite tips.  Scale bar = 20 microns 
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Table 1. Clinical phenotype of the three patients with KIDINS220 de novo variants. 
 Patient 1 Patient 2 Patient 3 
Prenatal Scan Dilatation of lateral ventricles Dilatation of lateral ventricles Dilatation of lateral ventricles 
Polyhidramnious - + ? 
Gestational age (weeks) 38 40 41 
Weight (birth) 
Weight (Infancy) 
Weight (Puberty) 
2.26kg (2nd centile) 
>99.6th centile 
>99.6th centile  
3.65kg (75th centile) 
99.6th centile 
>99.6th centile 
3.28 (50th centile) 
98th centile 
Overweight 
Height (infancy) 
Height (Puberty) 
91st – 98th centile 
91s t  centile  
91st  centile 
91s t  centile 
75th centile 
? 
OFC (birth) 
OFC (infancy) 
OFC (puberty) 
25th -50th centile 
>>99.6th centile   
99.6th centile 
? 
99.6th centile 
>99.6th centile 
? 
98th centile 
25th – 50th centile 
Feeding pattern Nl Nl Nl 
Dysmorphic features Brachyplagiocephaly 
Bossed forehead  
Deep set eyes 
Brachyplagiocephaly 
Prominent forehead  
Deep-set eyes  
Crowded teeth 
Brachyplagiocephaly 
Prominent forehead  
 
Vision Reduced acuity 
Hypermetropia 
Astigmatism  
Squint 
Hypermetropia 
Astigmatism 
Squint 
Hypermetropia 
Esotropia 
Nystagmus + + + 
ERG Nl ? ? 
VEP Post retinal dysfunction ? ? 
Development Delayed Delayed Delayed 
Neurology Axial hypotonia 
Spastic paraplegia 
Spastic paraplegia Spastic paraplegia 
Brain MRI Dilated, lateral and third ventricles   
Normal fourth ventricle Reduced 
white matter bulk 
Mild delay in myelination 
Mild generalised atrophy 
Dilated, third and lateral ventricles  
Normal fourth ventricle  
Reduced white matter bulk  
Mild generalised atrophy 
Dilated  lateral ventricles  
High riding 3rd ventricle  
Partial agenesis of corpus callosum 
Bone age ? Slightly delayed ? 
Eating habits Nl Nl Nl 
Development Moderate global delay Moderate global delay Moderate global delay 
Nl: normal, +: present, -: absent,?: not reported, OFC: OccipitoFrontalCircumference. ERG: Electroretinogram. VEP: Visual Evoked 
Potential.   
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Abbreviations 
ATE: Alternative Terminal Exon  
ARMS: Ankyrin Repeat-rich Membrane Spanning 
BDNF: Brain-Derived Neurotrophic Factor 
DDD: Deciphering Developmental Disorders  
DMEM: Dulbecco’s Modified Eagle’s Medium 
EDTA: Ethylenediaminetetraacetic Acid 
EVS: Exome Variant Server 
ExAC: Exome Aggregation Consortium database 
FBS: Fetal Bovine Serum 
HAMF10: Ham’s F10 nutrient medium 
HEK293: Human Embryonic Kidney 293 cell line 
KIDINS220: Kinase D Interacting Substrate of 220 kDa 
KIF5A: Kinesin Family Member 5A 
KIM: Kinesin Light Chain Interactive Motif 
KLC: Kinesin Light Chain 
LOVD: Leiden Open Variation Database 
MOMO: Macrosomia, Obesity, Macrocephaly, and Ocular abnormalies  
NGS: Next Generation Sequencing  
NIHR: National Institute for Health Research 
NMD: Nonsense-Mediated Decay 
PAGE: Polyacrylamide Gel Electrophoresis 
PBS: Phosphate Buffered Saline 
PC12: Rat Pheochromocytoma cell line 
PFA: Paraformaldehyde 
PVDF: Polyvinylidene Difluoride 
RFP: Red Fluorescent Protein   
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SDS: Sodium Dodecyl Sulfate 
SINO: Spastic paraplegia, Intellectual disability, Nystagmus and Obesity syndrome 
SNX27: Sorting Nexin Family Member 27 
Trk: Tropomyosin Receptor Kinase 
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Figure 1: Clinical features of patients.  Note obesity, macrocephaly, brachycephaly and eye abnormalities.  
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Figure 2: De novo dominant nonsense variants in KIDINS220 A) Variants p.(Trp1350*) and p.(Gln1366*) 
result in truncated protein without the full KIM domain, and p.(Leu1507Phefs*4) results in a slightly longer 
protein containing the full KIM domain.   B) Comparison of the wild-type KIDINS220 exonic structure versus 
an alternate terminal ending splice variant described by Schmieg et al.(8) and the three patients described 
in this study C) KIDINS220 cDNA sequencing verifies that there is no mRNA nonsense mediated decay in 
patient 1. Western blot analysis of (D) total extracts from patient 1 versus a control fibroblast and (E) total 
HEK293T extracts expressing wild-type and variant (Trp1350* and Gln1366*) forms of KIDINS220. 
Expression of KIDINS220 was tested with antibodies against the N-terminal part of KIDINS220 (Nterm Ab). 
The truncated protein products caused by KIDINS220 variants are indicated with a black arrow and the 
expected full-length wild-type protein product by a grey arrow. Anti-actin was used as a loading control for 
the fibroblasts and anti-tubulin for the HEK293T cells.  
190x268mm (300 x 300 DPI)  
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Figure 3. Effect of KIDINS220 and Trp1350* expression in zebrafish embryo motor neurons.  
A) Tissue-specific expression of KIDINS220 variants in 5 dpf zebrafish embryos was achieved by 
microinjection of UAS:KIDINS220 and UAS:Trp1350* DNA in  tg(Isl1BAC:GalFF; UAS:GFP) embryos (upper 
panel). A DNA UAS:RFP construct was co-injected (lower panel) to evaluate the efficiency of the 
microinjections. White arrowheads: axonic extensions of the motor neurons. B) 5 dpf zebrafish embryo 
(ventral view; anterior is left). White dotted line: position of kymographs presented in C. C) Visualization of 
spastic activity on thoracic kymographs. Representative kymographs of embryos showing no spastic activity 
(upper panel, no act.) and spastic activity (lower panel, spasm). Black arrowheads point at spastic events as 
visualized on the kymograph. Representative recordings are available as supplementary files. D) 
Quantification of spastic events in the different conditions of the study. Expression of KIDINS220 wt and 
Trp1350* in motor neurons results in increased spastic activity. No act.: No spastic activity. *:p<0.05; 
**:p<0.01; Fisher’s exact test. Scale bars: 1mm in A (left panels),B; 50 microns in A (right panels)  
148x138mm (300 x 300 DPI)  
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Figure 4: Kidins220 truncated variant is able to localize to neurite tips in Neuro-2A cells  
Representative image of transfected KIDINS220 wild-type and variant p.(Gln1366*) in differentiated Neuro-
2A cells. Immunofluorescence of cotransfected mCherry (red), anti-HA-tagged wild-type or p.(Gln1366*) 
KIDINS220 (green) show that the truncated KIDINS220 variant is transported to developing neurite 
tips.  Scale bar = 20 microns  
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